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	 A	new,	simple,	accurate,	and	precise	liquid	chromatographic	method	has	been	developed	and
validated	 for	 the	 determination	 of	 two	 novel	 dipeptidylpeptidase‐4	 (DPP‐4)	 inhibitors;
namely	vildagliptin	(VLG)	and	saxagliptin	HCl	(SXG)	simultaneously	 in	their	binary	mixtures
with	metformin	HCl	(MET).	Chromatographic	separation	was	achieved	on	an	Inertsil®	CN‐3
column	 (250	 mm	 x	 4.6	 mm,	 5	 µm).	 Isocratic	 elution	 using	 a	 mobile	 phase	 of	 potassium
dihydrogen	phosphate	buffer	pH	 (4.6)	 ‐	 acetonitrile	 (15:85,	v:v)	at	a	 flow	rate	of	 1	mL/min
with	UV	detection	at	208	nm	was	performed.	The	 liquid	chromatographic	method	was	used
for	the	simultaneous	determination	of	either	VLG,	SXG	and	MET	in	the	range	of	5‐200,	0.5‐20
and	50‐2000	μg/mL,	respectively.	The	methods	developed	were	satisfactorily	applied	 to	 the
analysis	 of	 the	 pharmaceutical	 formulations	 and	 proved	 to	 be	 specific	 and	 accurate	 for	 the
quality	control	of	the	cited	drugs	in	pharmaceutical	dosage	forms.	
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1.	Introduction	
	
Vildagliptin	(VDG),	S‐1‐[N‐(3‐hydroxy‐1‐adamantyl)	glycyl]	
pyrrolidine‐2‐carbonitrile	 (Figure	 1),	 is	 an	 oral	 hypoglycemic	
drug	 of	 the	 dipeptidylpeptidase‐4	 (DPP‐4)	 inhibitor	 class	 [1].	
DPP‐4	 inhibitors	represent	a	new	therapeutic	approach	to	 the	
treatment	of	type	2	diabetes	[2].	Literature	survey	reveals	that	
only	 one	 spectrophotometric	 method	 [3]	 and	 one	 chroma‐
tographic	method	was	reported	for	the	determination	of	VDG	in	
the	presence	of	its	synthetic	intermediate	[4].	
Saxagliptin	(SXG),	(1S,3S,5S)‐2‐[(2S)‐2‐amino‐2‐(3‐hydroxy	
‐1‐adamantyl)acetyl]‐	 2‐azabicyclo	 [3.1.0]	 hexane‐3‐carbo‐
nitrile	 (Figure	 1),	 is	 another	 new	 dipeptidylpeptidase‐4	
(DPP‐4)	 inhibitor	 [5].	 SXG	 was	 recently	 approved	 for	 the	
treatment	 of	 type	 2	 diabetes	 mellitus	 [6].	 Literature	 survey	
reveals	that	only	one	LC‐MS/MS	[7]	has	been	reported	for	SXG.	
Besides,	 another	 LC	 method	 with	 UV	 detection	 [8]	 and	 a	
spectrophotometric	 method	 [9]	 have	 been	 reported	 for	 the	
determination	of	the	drug.	
Metformin	 hydrochloride	 (MET),	 N,N‐dimethylimido‐	
dicarbonimidic	diamide	(Figure	1),	is	a	biguanide	hypoglycemic	
drug	 that	 is	 regarded	 as	 the	main	 drug	 in	mixed	 therapies	 of	
oral	 hypoglycemics.	 Literature	 survey	 reveals	 that	 some	
methods	 have	 been	 reported	 for	 determination	 of	 MET	 in	
mixtures	including	LC/MS/MS	[10]	and	HPLC	[11‐14].	
Due	 to	 the	 lack	 of	 reported	 LC	 methods	 describing	
determination	 of	 the	 mixtures	 under	 investigation,	 it	 was	
deemed	 useful	 to	 develop	 simple,	 sensitive	 and	 selective	 LC	
method	 that	 could	 be	 useful	 for	 the	 simultaneous	
determination	 of	 VDG	 and	 MET	 or	 the	 simultaneous	
determination	 of	 SXG	 and	 MET.	 The	 proposed	 method	 was	
designed	 to	 be	 suitable	 for	 the	 quality	 assessment	 of	 these	
mixtures	in	pharmaceutical	preparations.		
	
(a)	
	
	
	
(b)	
	
	
	
(c)	
	
Figure	 1.	 Chemical	 structures	 of	 vildagliptin	 (a),	 saxagliptin	 (b)	 and	
metformin	(c).	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
The	 HPLC	 system	 consisted	 of	 a	 Schimadzu	 LC‐20	 AT	
Liquid	Chromatograph	(Japan)	using	an	Inertsil® CN‐3	column	
(250	mm	x	4.6	mm,	5	µm).	The	system	was	equipped	with	a	UV‐
visible	detector	(SPD‐20A,	Japan)	and	an	autosampler	(SIL‐20A,	
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Schimadzu,	 Japan).	 An	 Elma	 S100	 ultrasonic	 processor	model	
KBK	4200	(Germany)	was	used	for	the	degassing	of	the	mobile	
phases.	
	
2.2.	Reagents	and	reference	samples	
	
Pharmaceutical	grade	VDG,	certified	to	contain	99.70%	and	
Eucreas®	tablets,	nominally	containing	50	mg	VDG	and	500	mg	
of	 MET	 per	 tablet,	 were	 supplied	 from	 Novartis	 Europharm	
limited	 company	 (London,	 United	 Kingdom).	 Pharmaceutical	
grade	 SXG,	 certified	 to	 contain	 99.85%	 and	 Kombiglyze®	
tablets,	 nominally	 containing	 5.58	 mg	 of	 SXG	 and	 500	 mg	 of	
MET	 per	 tablet,	 were	 supplied	 by	 Bristol‐Myers	 Squibb/	
AstraZeneca	 EEIG	 (United	 Kingdom).	 Pharmaceutical	 grade	
MET,	 certified	 to	 contain	 99.79%	 was	 supplied	 by	 Chemical	
Industries	 Development	 (CID)	 Co.	 (Giza,	 Egypt).	 Methanol	
(HiPerSolv	 for	 HPLC),	 acetonitrile	 (HiPerSolv),	 potassium	
dihydrogen	 phosphate	 and	 orthophosphoric	 acid	 (85%)	were	
obtained	 from	 VWR	 Chemicals	 (Pool,	 England).	 Bi‐distilled	
water	was	produced	 in‐house	 (Aquatron	Water	 Still,	 A4000D,	
UK).	Membrane	 filters	 0.45	µm	 from	Teknokroma	 (Barcelona,	
Spain)	were	used.	All	other	chemicals	and	reagents	used	were	
of	 analytical	 grade	unless	 indicated	otherwise.	 Standard	stock	
solutions	of	each	drug	(1	mg/mL)	were	prepared	by	dissolving	
100	mg	of	 the	drug	 in	methanol	 in	a	100	mL	volumetric	 flask	
and	 then	 completed	 to	 volume	with	methanol.	 Then	 required	
concentrations	 were	 prepared	 by	 serial	 dilutions	 with	
methanol	of	these	stock	solutions.	
	
2.3.	Chromatographic	conditions	
	
Chromatographic	separation	was	achieved	on	an	Inertsil® 
CN‐3	column	(250	mm	x	4.6	mm,	5	µm).	Isocratic	elution	using	
a	mobile	phase	consisting	of	potassium	dihydrogen	phosphate	
buffer	pH	(4.6)	 ‐	acetonitrile	(15:85,	v:v)	with	UV	detection	at	
208	 nm	 was	 performed.	 The	 buffer	 solution	 was	 filtered	
through	0.45	µm	membrane	 filter	 and	degassed	 for	30	min	 in	
an	ultrasonic	bath	prior	to	use.	The	mobile	phase	was	pumped	
through	the	column	at	a	flow	rate	of	1	mL/min.	Analyses	were	
performed	 at	 ambient	 temperature	 and	 the	 injection	 volume	
was	25	µL.	
	
2.4.	Samples’	preparation	
	
Twenty	 tablets	 of	 each	 mixture	 were	 weighed.	 An	
accurately	weighed	 amount	 of	 the	 finely	 powdered	 Eucreas®	
tablets	equivalent	to	100	mg	of	VDG	and	1000	mg	of	MET	was	
made	 up	 to	 100	 mL	 with	 methanol.	 An	 accurately	 weighed	
amount	of	the	finely	powdered	Kombiglyze®	tablets	equivalent	
to	11.16	mg	of	SXG	and	1000	mg	of	MET	were	made	up	to	100	
mL	 with	 methanol.	 The	 solutions	 were	 filtered	 followed	 by	
serial	 dilution	 to	 the	 required	 concentrations	 for	 each	
experiment.	
	
2.5.	Procedure	
	
2.5.1.	Linearity	and	repeatability	
	
Accurately	 measured	 aliquots	 of	 working	 standard	
solutions	equivalent	to	50‐2000	µg	VLG,	5.0‐200.0	µg	SXG	and	
0.5‐20.0	mg	MET	were	separately	transferred	into	two	series	of	
10	mL	 volumetric	 flasks	 and	 then	 completed	 to	 volume	 with	
methanol.	A	volume	of	25	µL	of	each	solution	was	injected	into	
the	 chromatograph.	 The	 chromatographic	 conditions	
mentioned	in	Section	2.3.	including	the	mobile	phase	at	a	flow	
rate	1	mL/min,	detection	at	208	nm	and	run	time	program	for	
12.5	min	were	adjusted.	A	calibration	curve	for	each	drug	was	
obtained	 by	 plotting	 area	 under	 the	 peak	 (AUP)	 against	
concentration	 (C).	 The	 repeatability	 of	 the	 method	 was	
assessed	by	analyzing	a	mixture	containing	100	µg/mL	of	VDG	
and	1000	µg/mL	of	MET,	and	another	mixture	containing	11.16	
µg/mL	of	SXG	and	1000	µg/mL	of	MET	(n	=	6).	The	%	R.S.D.	for	
the	peak	area	and	retention	 time	was	calculated	 (Table	1	and	
2).		
	
Table	 1.	 System	 suitability	 test	 for	 the	 proposed	 LC	 method	 for	 the	
determination	of	vildagliptin	in	binary	mixture	with	metformin.	
Item VDG	 MET
N	 2135	 2975	
R	 3.1	 3.1	
T 1.02	 1.10
RSD%	of	Peak	area	(6	injections)	 0.57	 0.69
RSD%	of	Retention	time	(	6	injections)	 0.16	 0.28
	
	
Table	 2.	 System	 suitability	 test	 for	 the	 proposed	 LC	 method	 for	 the	
determination	of	saxagliptin	in	binary	mixture	with	metformin.	
Item SXG	 MET
N 1811		 2835
R 3.9	 3.9
T 1.00		 1.09
RSD%	of	Peak	area	(6	injections) 0.71	 0.62
RSD%	of	Retention	time	(6	injections)		 0.28	 0.19	
	
	
2.5.2.	Assay	of	drugs	in	laboratory	prepared	mixtures	and	in	
pharmaceutical	preparations	
	
The	 procedure	 mentioned	 in	 Section	 2.5.1	 was	 repeated	
using	 two	 sets	 of	 laboratory	 prepared	mixtures	 equivalent	 to	
100‐1450	 µg/mL	 MET	 with	 10‐145	 µg/mL	 VLG	 and	 2‐13	
µg/mL	 SXG	 in	 different	 concentration	 ratios.	 For	 the	
determination	 of	 the	 examined	 drugs	 in	 Eucreas®	 and	
Kombiglyze®	tablets,	the	samples’	solutions	prepared	in	Section	
2.4	were	serially	diluted	to	prepare	solutions	equivalent	to	15‐
75	 and	 150‐750	 µg/mL	 of	 VLD	 and	 MET,	 respectively;	 and	
equivalent	 to	 1.67‐8.37	 and	 150‐750	 µg/mL	 of	 SXD	 and	MET,	
respectively;	 and	 then	 injected	 in	 triplicates.	 The	
concentrations	 of	 the	 examined	 drugs	were	 calculated	 by	 the	
calibration	equations	(Table	3).	
	
3.	Results	and	discussion	
	
The	combinations	of	VDG	or	SXG	with	MET	are	new	to	the	
market.	 No	 previous	 method	 was	 reported	 for	 the	 LC	
determination	of	VDG	or	SXG	in	their	binary	mixture	with	MET.	
Thus,	 the	 aim	 of	 this	work	was	 to	 develop	 a	 simple,	 accurate	
and	 reproducible	 LC	 method	 that	 could	 be	 applied	 to	 the	
simultaneous	determination	of	VDG	or	 SXG	with	MET	 in	 their	
laboratory	prepared	mixtures	 or	pharmaceutical	 preparations	
of	these	drugs.		
	
3.1.	Method	development	
	
During	 the	 optimization	 cycle,	 several	 chromatographic	
conditions	 were	 attempted	 using	 an	 Inertsil® CN‐3	 column	
(250	mm	x	4.6	mm,	5	µm).	Recently,	cyano	columns	have	been	
used	 for	 the	 separation	 and	 quantitation	 of	 drugs	 [15‐16].	
Various	mobile	phase	compositions	containing	different	ratios	
of	organic	and	aqueous	phases	were	tried	in	an	isocratic	mode.	
It	was	found	that	85%	of	organic	modifier	was	needed	to	elute	
all	 peaks	within	 10	min.	 Acetonitrile	 was	 found	 optimum	 for	
the	 elution.	 Besides,	 different	 buffers	 at	 different	 pH	 values	
were	 attempted	 along	 with	 acetonitrile.	 Therefore,	 a	 mobile	
phase	consisting	of	potassium	dihydrogen	phosphate	buffer	pH	
(4.6)	‐	acetonitrile	(15:85,	v:v)	and	pumped	at	a	flow	rate	of	1.0	
mL/min,	 in	 an	 isocratic	 mode,	 gave	 good	 separation	 of	 the	
three	drugs.	Due	to	the	poorly	absorbing	chromophores	in	the	
three	drugs	examined,	detection	was	carried	out	at	208	nm	to	
obtain	 sufficient	 peak	 intensity	 for	 these	drugs.	The	 retention	
times	 were	 7.2,	 6.3	 and	 8.7	 min	 for	 VLD,	 SXG	 and	 MET,	
respectively;	as	presented	in	Figure	2	and	3.	
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Table	3.	Results	obtained	by	LC	method	for	the	determination	of	metformin	in	binary	mixture	with	vildagliptin	or	saxagliptin.	
Item	 Metformin	 Vildagliptin	 Saxagliptin	
Retention	time	(min)	 8.7	 7.2 6.3
Wavelength	of	detection		 208	nm	 208	nm 208	nm	
Range	of	linearity	 50‐2000	μg/mL	 5‐200	μg/mL	 0.5‐20	μg/mL	
Regression	equation		 Area	x	10‐6	=	0.0528	Cμg/mL	+	0.0231		 Area	x	10‐5	=	0.1126	Cμg/mL	+	0.4040		 Area	x	10‐5	=	0.2415	Cμg/mL	+	0.5112	
Regression	coefficient	(r2)	 0.9999	 0.9996	 0.9968	
LOD	μg/mL	 19.36	 0.53	 0.29	
LOQ	μg/mL	 46.54	 1.78 0.48	
Sb	 2.1	x	10‐4	 1.1	x	10‐3 6.7	x	10‐2	
Sa	 2.7	x	10‐2	 0.15 0.58	
Confidence	limit	of	the	slope	 0.0528	±	0.14	x	10‐2	 0.1126	±	0.02	 0.2415	±	0.14		
Confidence	limit	of	the	intercept	 0.0231	±	0.05	x	10‐4	 0.4040	±	0.44	x	10‐3 0.5112	±	3.43	x	10‐2	
Standard	error	of	the	estimation	 0.341	 0.186 0.489	
Intraday	%	R.S.D.	 0.38‐0.87	 0.37‐0.68 0.33‐0.57	
Interday	%	R.S.D.	 0.33‐1.22	 0.41‐1.51	 0.54‐1.18	
Drug	in	lab.	prepared	mixture		 100.12	±	0.99	 99.49	±	0.90	 100.30	±	1.25	
Drug	in	dosage	form	 100.42	±	0.92	(Eucreas®)		
99.87	±	0.81	(Kombiglyze®)	
100.11	±	0.67	 99.47	±	1.15	
Drug	added	 100.83	±	1.30	(Eucreas®)	
100.17	±	0.86	(Kombiglyze®)	
100.53	±	0.89 100.64	±	1.40	
	
	
 
	
Figure	2.	A	 typical	LC	chromatogram	of	25	µL	 injector	of	Eucreas® sample	
solution	 containing	 (a)	 metformin	 hydrochloride	 (400	 µg/mL)	 and	 (b)	
vildagliptin	(40	µg/mL).	
	
	
 
	
Figure	 3.	 A	 typical	 LC	 chromatogram	 of	 25	 µL	 injector	 of	 Kombiglyze®
sample	 solution	 containing	 (a)	metformin	 hydrochloride	 (500	 µg/mL)	 and	
(b)	saxagliptin	hydrochloride	(5.58	µg/mL).	
	
3.2.	System	suitability	tests	
	
According	 to	 the	United	States	Pharmacopoeia,	 2007	 [17],	
system	 suitability	 tests	 are	 an	 integral	 part	 of	 liquid	
chromatographic	 methods	 in	 the	 course	 of	 optimizing	 the	
conditions	of	the	proposed	method.	In	the	proposed	LC	method,	
system	 suitability	 tests	 are	 used	 to	 verify	 that	 resolution	 and	
reproducibility	 were	 adequate	 for	 analysis	 performed.	
Different	parameters	affecting	the	chromatographic	separation	
were	studied.	The	parameters	of	this	test	are	column	efficiency	
(number	of	theoretical	plates),	tailing	of	chromatographic	peak,	
peak	 resolution	 factor,	 and	 repeatability	 as	 %R.S.D.	 of	 peak	
areas	 for	 six	 injections	 and	 reproducibility	 of	 retention	 times.	
The	results	of	these	tests	are	listed	in	Table	1	and	2.	
	
3.3.	Method	validation	
	
3.3.1.	Linearity	
	
Linearity	 was	 studied	 for	 VDG,	 SXG	 and	 MET.	 A	 linear	
relationship	 between	 area	 under	 the	 peak	 (AUP)	 and	
component	 concentration	 (C)	 was	 obtained.	 The	 regression	
equations	were	also	computed.	The	linearity	of	the	calibration	
curves	 were	 validated	 by	 the	 high	 value	 of	 correlation	
coefficients.	 The	 analytical	 data	 of	 the	 calibration	 curves	
including	 standard	 deviations	 for	 the	 slope	 and	 intercept	 (Sb,	
Sa)	are	summarized	in	Table	3.	
	
3.3.2.	Accuracy	
	
Accuracy	of	the	results	was	calculated	by	%	recovery	of	five	
different	 samples	 of	 the	 laboratory	prepared	mixtures	 of	VLD	
and	SXG	in	their	binary	mixture	with	MET	and	also	by	standard	
addition	 technique	 for	Eucreas®	and	Kombiglyze®	 tablets.	The	
results	 obtained	 including	 the	 mean	 of	 the	 recovery	 and	
relative	standard	deviation	are	displayed	in	Table	3.	
	
3.3.3.	Precision	
	
The	repeatability	of	the	method	was	assessed	by	analyzing	
100	µg/mL	of	VLG,	11.16	µg/mL	of	SXG	and	1000	µg/mL	of	MET	
(n	=	6).	The	values	of	 the	precision	 (%R.S.D.)	 of	 repeatability,	
inter‐day	 and	 intra‐day	 precision	 (using	 three	 different	
concentrations	 in	 triplicates	 for	 three	 days)	 are	 displayed	 in	
Table	1‐3.	
	
3.3.4.	Specificity	
	
Specificity	is	the	ability	of	the	analytical	method	to	measure	
the	 analyte	 response	 in	 the	 presence	 of	 interferences.	 Due	 to	
lack	 of	 the	 degradation	 profile	 of	 the	 studied	 gliptins,	
interferences	 due	 to	 the	 degradation	 products	 could	 not	 be	
studied.	 In	 the	 present	 work,	 specificity	 was	 checked	 by	
analyzing	 VDG	 with	 MET	 and	 SXG	 with	 MET	 in	 laboratory	
prepared	 mixtures.	 Good	 resolution	 and	 absence	 of	
interference	between	drugs	being	analyzed	are	shown	in	Figure	
2	 and	 3.	 Besides,	 the	 chromatograms	 of	 the	 pharmaceutical	
formulation	 samples	were	 checked	 for	 the	 appearance	 of	 any	
extra	peaks.	No	chromatographic	 interference	from	any	of	 the	
excipients	 was	 found	 at	 the	 retention	 times	 of	 the	 examined	
drugs	(Figure	2	and	3).		
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Table	4.	Statistical	comparison	between	the	results	of	the	proposed	LC	method	and	the	reference	method	for	the	determination	of	metformin.	
Statistical	term	 Reference	methodb Proposed	method	
Mean 100.4	 100.12
S.D.	±	 0.28	 0.99	
S.E.	±	 0.13 0.44	
%	R.S.D.	 0.28	 0.99	
n	 5	 5	
V	 0.08	 0.98
t	(	a	2.306) ‐	 0.61
F	(	a	6.39)	 ‐	 0.08
a	Figures	in	parentheses	are	the	theoretical	t	and	F	values	at	(p=0.05).	
b	Reference	method	for	the	spectrophotometric	determination	of	metformin	in	the	Indian	pharmacopeia	[18].	
	
Table	5.	Statistical	comparison	between	the	results	of	the	LC	method	and	the	reference	methods	for	the	determination	of	vildagliptin	and	saxagliptin.	
Statistical	term	 Reference	method	for	vildagliptin	b HPLC	method Reference	method	for	saxagliptinc	 HPLC	method
Mean 100.01	 99.49 100.20 100.3
S.D.	±	 0.99	 0.90 1.10 1.25
S.E.	±	 0.44 0.40 0.49 0.56
%RSD	 0.99	 0.90 1.1 1.25
n	 5	 5	 5	 5	
V	 0.98	 0.81 1.21 1.56
t	(	a	2.306) ‐	 0.87	 ‐	 0.13	
F	(	a	6.39)	 ‐	 1.21	 ‐	 0.78	
a	Figures	in	parentheses	are	the	theoretical	t	and	F	values	at	(p=0.05).	
b	Reference	method:	aliquots	of	standard	solutions	in	distilled	water	containing	5‐25	μg/mL	VDG	were	measured	at	208	nm	using	water	as	a	blank	[3].	
c	Reference	method:	aliquots	of	standard	solutions	in	distilled	water	containing	5‐40	μg/mL	SXG	were	measured	at	208	nm	using	methanol	as	a	blank	[8].		
	
	
In	addition,	the	chromatograms	of	the	drugs	in	the	samples’	
solutions	were	found	identical	 to	 the	chromatograms	received	
by	 the	 standard	 solutions	 at	 the	 wavelengths	 applied.	
Moreover,	good	results	were	obtained	for	the	determination	of	
the	cited	drugs	in	the	two	dosage	forms,	Table	3.	These	results	
confirm	the	absence	of	interference	from	other	materials	in	the	
pharmaceutical	 formulations	 and	 therefore	 confirm	 the	
specificity	of	the	two	proposed	methods.		
	
3.3.5.	Robustness	
	
Robustness	 was	 performed	 by	 deliberately	 changing	 the	
chromatographic	conditions.	The	most	important	parameter	to	
be	studied	was	the	resolution	factor	between	the	peaks	of	VLG	
and	MET	and	also	between	the	peaks	of	SXG	and	MET.	The	flow	
rate	of	the	mobile	phase	was	changed	from	1.0	mL/min	to	0.8	
mL/min	 and	 1.2	 mL/min,	 where	 resolution	 factors	 obtained	
were	 (3.1‐3.9),	 (3.25‐4.11)	 and	 (3.15‐3.87),	 respectively.	 The	
organic	strength	was	changed	by	±%2,	where	resolution	factors	
obtained	were	(3.1‐3.9),	(3.22‐3.78)	and	(3.1‐4.0)	respectively.	
Finally,	a	value	of	pH	of	the	phosphate	buffer	was	varied	from	
4.6	to	4.5	and	4.7,	where	resolution	factors	obtained	were	(3.1‐
3.9),	(3.05‐4.25)	and	(2.95‐3.18),	respectively.	As	it	can	be	seen	
from	 these	 results,	 good	 values	 of	 the	 resolution	 factor	were	
obtained	for	all	these	variations,	indicating	good	robustness	of	
the	proposed	LC	method.	
	
3.3.6.	Limit	of	detection	and	limit	of	quantification	
	
Limit	 of	 detection	 (LOD)	 which	 represents	 the	
concentration	 of	 analyte	 at	 S/N	 ratio	 of	 3	 and	 limit	 of	
quantification	 (LOQ)	 at	 which	 S/N	 is	 10	 were	 determined	
experimentally	for	the	proposed	methods	and	results	are	given	
in	Table	3.	
	
3.3.7.	Statistical	analysis	
	
Statistical	analysis	of	the	results	obtained	by	the	proposed	
methods	and	the	reference	methods	for	each	drug	were	carried	
out	 by	 “SPSS	 statistical	 package	 version	 11”.	 The	 significant	
difference	 between	 the	 reference	 methods	 and	 the	 described	
methods	was	tested	by	one	way	ANOVA	(F‐test)	at	p	=	0.05	as	
shown	in	Table	4	and	5.	The	test	ascertained	that	there	was	no	
significant	difference	among	the	methods.	
	
	
4.	Conclusion	
	
A	 single	 LC	 method	 can	 be	 applied	 to	 the	 simultaneous	
determination	of	VDG	and	SXG	with	metformin.	The	proposed	
LC	method	has	the	advantages	of	simplicity,	precision,	accuracy	
and	convenience	for	the	separation	and	quantization	of	VDG	or	
SXG	 in	combination	with	MET.	The	method	can	be	applied	for	
the	 determination	 of	 the	 cited	 drugs	 in	 tablets	 without	
interference	from	the	tablets’	inactive	ingredients.	The	method	
was	 validated	 showing	 satisfactory	 data	 for	 all	 the	 method	
validation	parameters	tested.	Thus,	 the	developed	method	can	
be	conveniently	used	by	quality	control	laboratories.	
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